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BACKGROUND
The annual healthcare expenditure in the United States for the management of Clostridium difficile infection (CDI) is estimated to be 3.2 billion dollars. These costs are rising with increased rate of CDI since 2000. Recurrent CDI (RCDI) occurs in 10-20% of patients after initial treatment. In this population, the rate of additional recurrences increases to 40-65%. Guidelines recommend the use of fecal microbiota transplant (FMT) after a third relapse of CDI. We evaluated the efficacy as well as the healthcare savings provided by FMT in patients with RCDI.
DISCUSSION
FMT is an effective modality for treating patients with RCDI with mean primary cure rates of 91%. Our primary cure rate of 83.7% represents an improvement over usual antibiotic therapy. Conservative estimates are each patient treated with successful FMT saves $17,000 in healthcare costs. Using this, the 38 successful FMT procedures performed over a 20-month period led to $646,000 in savings. The cost of the 60 samples used or discarded in the treatment of these patients was $20,100. One unique finding was the association of inadequate bowel preparation and successful treatment. It is possible that patients who are unable to adequately clear their colon before a procedure may be more likely to retain the transplanted fecal material, giving it an extended period to take effect.
We performed a retrospective single-center study at a large tertiary care teaching hospital. A chart review of patients who had undergone FMT between October 1, 2015 and May 30, 2017 was done. Patients were eligible for FMT treatment if they had at least three recurrent episodes of CDI with at least one trial of pulsed-dose oral vancomycin. In eligible patients 250 mL of donor fecal material was endoscopically delivered in the right colon. Phone call follow up was performed one week after FMT to assess for symptom resolution. 
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